RNAi in clinical studies

Current Medicinal Chemistry

Volumn 20, Issue 14, 2013, Pages 1801-1816

  Kubowicz, P ^a   Zelaszczyk, D ^b   Pekala, E ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Cancer; Clinical trials; MiRNA; Post transcriptional gene silencing; RNA interference; RNAi based therapies; SiRNA

Indexed keywords

ALN PCS 02; ALN RSV 01; ALN TTR 02; ALN VSP 02; ARGONAUTE 2 PROTEIN; ATU 027; BEVASIRANIB; CALAA 01; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIN DEPENDENT KINASE 5; DNA DIRECTED RNA POLYMERASE III; EPHRIN RECEPTOR A2; FANG; INHIBITOR OF APOPTOSIS PROTEIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MICRORNA; NESTIN; REACTIVE OXYGEN METABOLITE; RIBONUCLEASE III; RXI 109; SHORT HAIRPIN RNA; SPC 2996; SYL 040012; TD 101; TKM EBOLA; TKM PLK 1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN C;

AMYLOIDOSIS; ANGIOGENESIS; ANTIVIRAL THERAPY; APOPTOSIS; ARTICLE; CAENORHABDITIS ELEGANS; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONGENITAL PACHYONYCHIA; DNA REPLICATION; DOWN REGULATION; DROSOPHILA MELANOGASTER; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; FILOVIRUS INFECTION; GENE EXPRESSION; GENETIC CODE; HETEROCHROMATIN; HUMAN; HYDROLYSIS; HYPERCHOLESTEROLEMIA; INJECTION SITE ERYTHEMA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LIVER CANCER; LUNG CANCER; METASTASIS; NONHUMAN; OPEN ANGLE GLAUCOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSTTRANSCRIPTIONAL GENE SILENCING; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETINA MACULA AGE RELATED DEGENERATION; RNA INTERFERENCE; RNA SEQUENCE; SCAR; SOLID TUMOR; TUMOR INVASION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; VIRUS ENTRY; WOUND HEALING;

ANIMALS; GENETIC THERAPY; HUMANS; MICRORNAS; MODELS, ANIMAL; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84877973425     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990118     Document Type: Article

References (141)

1. Wang, Z.; Rao, D. D.; Senzer, N.; Nemunaitis, J. RNA Interference and Cancer Therapy. Pharm. Res., 2011, 28 (12), 2983-2995.
2. Fire, A.; Xu, S.; Montgomery, M. K.; Kostas, S. A.; Driver, S. E.; Mello, C. C. Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature, 1998, 391 (6669), 806-811. (Pubitemid 28099681)
3. Hammond, S. M.; Caudy, A. A.; Hannon, G. J. Post-transcriptional gene silencing by double-stranded RNA. Nat. Rev. Genet., 2001, 2 (2), 110-119. (Pubitemid 33674002)
4. Zamore, P. D.; Tuschl, T.; Sharp, P. A.; Bartel, D. P. RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell, 2000, 101 (1), 25-33.
5. Ambros, V.; Bartel, B.; Bartel, D. P.; Burge, C. B.; Carrington, J. C.; Chen, X.; Dreyfuss, G.; Eddy, S. R.; Griffiths-Jones, S.; Marshall, M.; Matzke, M.; Ruvkun, G.; Tuschl, T. A uniform system for microRNA annotation. RNA, 2003, 9 (3), 277-279. (Pubitemid 36246165)
6. Rychahou, P. G.; Jackson, L. N.; Farrow, B. J.; Evers, B. M. RNA interference: Mechanisms of action and therapeutic consideration. Surgery, 2006, 140 (5), 719-725. (Pubitemid 44648184)
7. Klase, Z.; Winograd, R.; Davis, J.; Carpio, L.; Hildreth, R.; Heydarian, M.; Fu, S.; McCaffrey, T.; Meiri, E.; Ayash-Rashkovsky, M.; Gilad, S.; Bentwich, Z.; Kashanchi, F. HIV-1 TAR miRNA protects against apoptosis by altering cellular gene expression. Retrovirology., 2009, 6, 18.
8. Klase, Z.; Kale, P.; Winograd, R.; Gupta, M. V.; Heydarian, M.; Berro, R.; McCaffrey, T.; Kashanchi, F. HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR. BMC. Mol. Biol., 2007, 8, 63.
9. Bernstein, E.; Caudy, A. A.; Hammond, S. M.; Hannon, G. J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature, 2001, 409 (6818), 363-366. (Pubitemid 32151243)
10. Kisielow, M.; Kleiner, S.; Nagasawa, M.; Faisal, A.; Nagamine, Y. Isoform-specific knockdown and expression of adaptor protein ShcA using small interfering RNA. Biochem. J., 2002, 363 (Pt 1), 1-5. (Pubitemid 34280605)
11. Caudy, A. A.; Ketting, R. F.; Hammond, S. M.; Denli, A. M.; Bathoorn, A. M.; Tops, B. B.; Silva, J. M.; Myers, M. M.; Hannon, G. J.; Plasterk, R. H. A micrococcal nuclease homologue in RNAi effector complexes. Nature, 2003, 425 (6956), 411-414. (Pubitemid 37187271)
12. Robb, G. B.; Brown, K. M.; Khurana, J.; Rana, T. M. Specific and potent RNAi in the nucleus of human cells. Nat. Struct. Mol. Biol., 2005, 12 (2), 133-137.
13. Mittal, V. Improving the efficiency of RNA interference in mammals. Nat. Rev. Genet., 2004, 5 (5), 355-365. (Pubitemid 38529407)
14. Lee, Y.; Ahn, C.; Han, J.; Choi, H.; Kim, J.; Yim, J.; Lee, J.; Provost, P.; Radmark, O.; Kim, S.; Kim, V. N. The nuclear RNase III Drosha initiates microRNA processing. Nature, 2003, 425 (6956), 415-419. (Pubitemid 37187272)
15. Zeng, Y.; Yi, R.; Cullen, B. R. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc. Natl. Acad. Sci. U. S. A, 2003, 100 (17), 9779-9784. (Pubitemid 37087018)
16. Rao, D. D.; Vorhies, J. S.; Senzer, N.; Nemunaitis, J. siRNA vs. shRNA: Similarities and differences. Adv. Drug Deliv. Rev., 2009, 61 (9), 746-759.
17. Rao, D. D.; Senzer, N.; Wang, Z.; Kumar, P.; Jay, C. M.; Nemunaitis, J. Bifunctional short hairpin RNA (bi-shRNA): Design and pathway to clinical application. Methods Mol. Biol., 2013, 942, 259-278.
18. Abrusan, G.; Krambeck, H. J. Competition may determine the diversity of transposable elements. Theor. Popul. Biol., 2006, 70 (3), 364-375. (Pubitemid 44508694)
19. Ghildiyal, M.; Seitz, H.; Horwich, M. D.; Li, C.; Du, T.; Lee, S.; Xu, J.; Kittler, E. L.; Zapp, M. L.; Weng, Z.; Zamore, P. D. Endogenous siRNAs derived from transposons and mRNAs in Drosophila somatic cells. Science, 2008, 320 (5879), 1077-1081. (Pubitemid 351929549)
20. Reyes-Turcu, F. E.; Grewal, S. I. Different means, same endheterochromatin formation by RNAi and RNAi-independent RNA processing factors in fission yeast. Curr. Opin. Genet. Dev., 2012.
21. Zofall, M.; Yamanaka, S.; Reyes-Turcu, F. E.; Zhang, K.; Rubin, C.; Grewal, S. I. RNA elimination machinery targeting meiotic mRNAs promotes facultative heterochromatin formation. Science, 2012, 335 (6064), 96-100.
22. Voinnet, O. RNA silencing as a plant immune system against viruses. Trends Genet., 2001, 17 (8), 449-459. (Pubitemid 32727237)
23. Stein, C. A.; Krieg, A. M. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res. Dev., 1994, 4 (2), 67-69. (Pubitemid 24308373)
24. Pieken, W. A.; Olsen, D. B.; Aurup, H.; Williams, D. M.; Heidenreich, O.; Benseler, F.; Eckstein, F. Structure-function relationship of hammerhead ribozymes as probed by 2'-modifications. Nucleic Acids Symp. Ser., 1991, (24), 51-53.
25. Love, K. T.; Mahon, K. P.; Levins, C. G.; Whitehead, K. A.; Querbes, W.; Dorkin, J. R.; Qin, J.; Cantley, W.; Qin, L. L.; Racie, T.; Frank-Kamenetsky, M.; Yip, K. N.; Alvarez, R.; Sah, D. W.; de, F. A.; Fitzgerald, K.; Koteliansky, V.; Akinc, A.; Langer, R.; Anderson, D. G. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl. Acad. Sci. U. S. A, 2010, 107 (5), 1864-1869.
26. Shang, X.; Wang, Y.; Zhao, Q.; Wu, K.; Li, X.; Ji, X.; He, R.; Zhang, W. siRNAs target sites selection of ezrin and the influence of RNA interference on ezrin expression and biological characters of osteosarcoma cells. Mol. Cell Biochem., 2012.
27. Jackson, A. L.; Burchard, J.; Schelter, J.; Chau, B. N.; Cleary, M.; Lim, L.; Linsley, P. S. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA., 2006, 12 (7), 1179-1187. (Pubitemid 43990543)
28. Qiu, S.; Adema, C. M.; Lane, T. A computational study of offtarget effects of RNA interference. Nucleic Acids Res., 2005, 33 (6), 1834-1847. (Pubitemid 41748330)
29. Hornung, V.; Guenthner-Biller, M.; Bourquin, C.; Ablasser, A.; Schlee, M.; Uematsu, S.; Noronha, A.; Manoharan, M.; Akira, S.; de, F. A.; Endres, S.; Hartmann, G. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med., 2005, 11 (3), 263-270. (Pubitemid 40460553)
30. Goodchild, A.; Nopper, N.; King, A.; Doan, T.; Tanudji, M.; Arndt, G. M.; Poidinger, M.; Rivory, L. P.; Passioura, T. Sequence determinants of innate immune activation by short interfering RNAs. BMC. Immunol., 2009, 10, 40.
31. Grishok, A.; Mello, C. C. RNAi (Nematodes: Caenorhabditis elegans). Adv. Genet., 2002, 46, 339-360.
32. Lee, N. S.; Dohjima, T.; Bauer, G.; Li, H.; Li, M. J.; Ehsani, A.; Salvaterra, P.; Rossi, J. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol., 2002, 20 (5), 500-505. (Pubitemid 34495938)
33. Tuschl, T. Expanding small RNA interference. Nat. Biotechnol., 2002, 20 (5), 446-448. (Pubitemid 34495927)
34. Leung, R. K.; Whittaker, P. A. RNA interference: From gene silencing to gene-specific therapeutics. Pharmacol. Ther., 2005, 107 (2), 222-239. (Pubitemid 40910042)
35. Miyagishi, M.; Taira, K. Strategies for generation of an siRNA expression library directed against the human genome. Oligonucleotides., 2003, 13 (5), 325-333. (Pubitemid 38404817)
36. Wang, Z.; Rao, D. D.; Senzer, N.; Nemunaitis, J. RNA interference and cancer therapy. Pharm. Res., 2011, 28 (12), 2983-2995.
37. Elbashir, S. M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001, 411 (6836), 494-498. (Pubitemid 32494397)
38. Kittler, R.; Putz, G.; Pelletier, L.; Poser, I.; Heninger, A. K.; Drechsel, D.; Fischer, S.; Konstantinova, I.; Habermann, B.; Grabner, H.; Yaspo, M. L.; Himmelbauer, H.; Korn, B.; Neugebauer, K.; Pisabarro, M. T.; Buchholz, F. An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division. Nature, 2004, 432 (7020), 1036-1040. (Pubitemid 40052235)
39. Zheng, L.; Liu, J.; Batalov, S.; Zhou, D.; Orth, A.; Ding, S.; Schultz, P. G. An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc. Natl. Acad. Sci. U. S. A, 2004, 101 (1), 135-140. (Pubitemid 38084216)
40. Arts, G. J.; Langemeijer, E.; Tissingh, R.; Ma, L.; Pavliska, H.; Dokic, K.; Dooijes, R.; Mesic, E.; Clasen, R.; Michiels, F.; van der Schueren, J.; Lambrecht, M.; Herman, S.; Brys, R.; Thys, K.; Hoffmann, M.; Tomme, P.; van, E. H. Adenoviral vectors expressing siRNAs for discovery and validation of gene function. Genome Res., 2003, 13 (10), 2325-2332. (Pubitemid 37265998)
41. Rubinson, D. A.; Dillon, C. P.; Kwiatkowski, A. V.; Sievers, C.; Yang, L.; Kopinja, J.; Rooney, D. L.; Zhang, M.; Ihrig, M. M.; McManus, M. T.; Gertler, F. B.; Scott, M. L.; Van, P. L. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet., 2003, 33 (3), 401-406. (Pubitemid 36278858)
42. Brummelkamp, T. R.; Bernards, R.; Agami, R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell, 2002, 2 (3), 243-247. (Pubitemid 41043979)
43. Gresch, O.; Engel, F. B.; Nesic, D.; Tran, T. T.; England, H. M.; Hickman, E. S.; Korner, I.; Gan, L.; Chen, S.; Castro-Obregon, S.; Hammermann, R.; Wolf, J.; Muller-Hartmann, H.; Nix, M.; Siebenkotten, G.; Kraus, G.; Lun, K. New non-viral method for gene transfer into primary cells. Methods, 2004, 33 (2), 151-163. (Pubitemid 38569660)
44. Brazas, R. M.; Hagstrom, J. E. Delivery of small interfering RNA to mammalian cells in culture by using cationic lipid/polymerbased transfection reagents. Methods Enzymol., 2005, 392, 112-124. (Pubitemid 40092511)
45. Kunath, T.; Gish, G.; Lickert, H.; Jones, N.; Pawson, T.; Rossant, J. Transgenic RNA interference in ES cell-derived embryos recapitulates a genetic null phenotype. Nat. Biotechnol., 2003, 21 (5), 559-561. (Pubitemid 36532022)
46. Chen, C. C.; Chang, C. M.; Sun, C. P.; Yu, C. P.; Wu, P. Y.; Jeng, K. S.; Hu, C. P.; Chen, P. J.; Wu, J. C.; Shih, C. H.; Gershwin, M. E.; Tao, M. H. Use of RNA interference to modulate liver adenoma development in a murine model transgenic for hepatitis B virus. Gene Ther., 2012, 19 (1), 25-33.
47. Mousa, S. A.; Mousa, S. S. Current status of vascular endothelial growth factor inhibition in age-related macular degeneration. Bio-Drugs., 2010, 24 (3), 183-194.
48. Haussecker, D. The business of RNAi therapeutics. Hum. Gene Ther., 2008, 19 (5), 451-462. (Pubitemid 351748790)
49. McCaffrey, A. P.; Meuse, L.; Pham, T. T.; Conklin, D. S.; Hannon, G. J.; Kay, M. A. RNA interference in adult mice. Nature, 2002, 418 (6893), 38-39. (Pubitemid 34742563)
50. Bitko, V.; Musiyenko, A.; Shulyayeva, O.; Barik, S. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med., 2005, 11 (1), 50-55. (Pubitemid 40215837)
51. Shimizu, S.; Kamata, M.; Kittipongdaja, P.; Chen, K. N.; Kim, S.; Pang, S.; Boyer, J.; Qin, F. X.; An, D. S.; Chen, I. S. Characterization of a potent non-cytotoxic shRNA directed to the HIV-1 coreceptor CCR5. Genet. Vaccines. Ther., 2009, 7, 8.
52. Qin, X. F.; An, D. S.; Chen, I. S.; Baltimore, D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl. Acad. Sci. U. S. A, 2003, 100 (1), 183-188. (Pubitemid 36078049)
53. Giladi, H.; Ketzinel-Gilad, M.; Rivkin, L.; Felig, Y.; Nussbaum, O.; Galun, E. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol. Ther., 2003, 8 (5), 769-776. (Pubitemid 37527452)
54. Lavender, H.; Brady, K.; Burden, F.; Delpuech-Adams, O.; Denise, H.; Palmer, A.; Perkins, H.; Savic, B.; Scott, S.; Smith-Burchnell, C.; Troke, P.; Wright, J. F.; Suhy, D.; Corbau, R. In Vitro Characterization of the Activity of PF-05095808, a Novel Biological Agent for Hepatitis C Virus Therapy. Antimicrob. Agents Chemother., 2012, 56 (3), 1364-1375.
55. ElHefnawi, M.; Hassan, N.; Kamar, M.; Siam, R.; Remoli, A. L.; El-Azab, I.; AlAidy, O.; Marsili, G.; Sgarbanti, M. The design of optimal therapeutic small interfering RNA molecules targeting diverse strains of influenza A virus. Bioinformatics., 2011, 27 (24), 3364-3370.
56. Ge, Q.; Eisen, H. N.; Chen, J. Use of siRNAs to prevent and treat influenza virus infection. Virus Res., 2004, 102 (1), 37-42. (Pubitemid 38447247)
57. Kumar, P.; Sood, V.; Vyas, R.; Gupta, N.; Banerjea, A. C.; Khanna, M. Potent inhibition of influenza virus replication with novel siRNA-chimeric- ribozyme constructs. Antiviral Res., 2010, 87 (2), 204-212.
58. Kumar, R.; Adams, B.; Oldenburg, A.; Musiyenko, A.; Barik, S. Characterisation and expression of a PP1 serine/threonine protein phosphatase (PfPP1) from the malaria parasite, Plasmodium falciparum: Demonstration of its essential role using RNA interference. Malar. J., 2002, 1, 5.
59. Inokuchi, J.; Radin, N. S. Preparation of the active isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, inhibitor of murine glucocerebroside synthetase. J. Lipid Res., 1987, 28 (5), 565-571. (Pubitemid 17116188)
60. Kaidonis, X.; Liaw, W. C.; Roberts, A. D.; Ly, M.; Anson, D.; Byers, S. Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulphate storing mucopolysaccharidoses. Eur. J. Hum. Genet., 2010, 18 (2), 194-199.
61. Dziedzic, D.; Wegrzyn, G.; Jakobkiewicz-Banecka, J. Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: A potential therapeutic approach for Sanfilippo disease. Eur. J. Hum. Genet., 2010, 18 (2), 200-205.
62. Dziedzic, D.; Narajczyk, M.; Gabig-Ciminska, M.; Jakobkiewicz-Banecka, J. Simultaneous siRNA-mediated silencing of pairs of genes coding for enzymes involved in glycosaminoglycan synthesis. Acta Biochim. Pol., 2012, 59 (2), 293-298.
63. Carr, L. L.; Finigan, J. H.; Kern, J. A. Evaluation and treatment of patients with non-small cell lung cancer. Med. Clin. North Am., 2011, 95 (6), 1041-1054.
64. Howard, B. A.; Furumai, R.; Campa, M. J.; Rabbani, Z. N.; Vujaskovic, Z.; Wang, X. F.; Patz, E. F., Jr. Stable RNA interferencemediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res., 2005, 65 (19), 8853-8860. (Pubitemid 41377374)
65. Steeg, P. S. Metastasis suppressors alter the signal transduction of cancer cells. Nat. Rev. Cancer, 2003, 3 (1), 55-63. (Pubitemid 37328887)
66. Li, M.; Chen, H.; Diao, L.; Zhang, Y.; Xia, C.; Yang, F. Caveolin-1 and VEGF-C promote lymph node metastasis in the absence of intratumoral lymphangiogenesis in non-small cell lung cancer. Tumori, 2010, 96 (5), 734-743.
67. Feng, Y.; Hu, J.; Ma, J.; Feng, K.; Zhang, X.; Yang, S.; Wang, W.; Zhang, J.; Zhang, Y. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously downregulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways. Eur. J. Cancer, 2011, 47 (15), 2353-2363.
68. Muller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M. E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S. N.; Barrera, J. L.; Mohar, A.; Verastegui, E.; Zlotnik, A. Involvement of chemokine receptors in breast cancer metastasis. Nature, 2001, 410 (6824), 50-56. (Pubitemid 32225831)
69. Takanami, I. Overexpression of CCR7 mRNA in nonsmall cell lung cancer: Correlation with lymph node metastasis. Int. J. Cancer, 2003, 105 (2), 186-189. (Pubitemid 36505319)
70. Timoshenko, A. V.; Rastogi, S.; Lala, P. K. Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells. Br. J. Cancer, 2007, 97 (8), 1090-1098. (Pubitemid 47587011)
71. Kensler, T. W.; Wakabayashi, N.; Biswal, S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 89-116.
72. Singh, A.; Misra, V.; Thimmulappa, R. K.; Lee, H.; Ames, S.; Hoque, M. O.; Herman, J. G.; Baylin, S. B.; Sidransky, D.; Gabrielson, E.; Brock, M. V.; Biswal, S. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS. Med., 2006, 3 (10), e420.
73. Padmanabhan, B.; Tong, K. I.; Ohta, T.; Nakamura, Y.; Scharlock, M.; Ohtsuji, M.; Kang, M. I.; Kobayashi, A.; Yokoyama, S.; Yamamoto, M. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol. Cell, 2006, 21 (5), 689-700. (Pubitemid 43290735)
74. Singh, A.; Boldin-Adamsky, S.; Thimmulappa, R. K.; Rath, S. K.; Ashush, H.; Coulter, J.; Blackford, A.; Goodman, S. N.; Bunz, F.; Watson, W. H.; Gabrielson, E.; Feinstein, E.; Biswal, S. RNAimediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res., 2008, 68 (19), 7975-7984.
75. Srinivasula, S. M.; Ashwell, J. D. IAPs: What's in a name? Mol. Cell, 2008, 30 (2), 123-135. (Pubitemid 351626688)
76. Chen, Z.; Naito, M.; Hori, S.; Mashima, T.; Yamori, T.; Tsuruo, T. A human IAP-family gene, apollon, expressed in human brain cancer cells. Biochem. Biophys. Res. Commun., 1999, 264 (3), 847-854.
77. Sung, K. W.; Choi, J.; Hwang, Y. K.; Lee, S. J.; Kim, H. J.; Lee, S. H.; Yoo, K. H.; Jung, H. L.; Koo, H. H. Overexpression of Apollon, an antiapoptotic protein, is associated with poor prognosis in childhood de novo acute myeloid leukemia. Clin. Cancer Res., 2007, 13 (17), 5109-5114. (Pubitemid 47502078)
78. Lopergolo, A.; Pennati, M.; Gandellini, P.; Orlotti, N. I.; Poma, P.; Daidone, M. G.; Folini, M.; Zaffaroni, N. Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation. Br. J. Cancer, 2009, 100 (5), 739-746.
79. Huang, Y. L.; Wu, C. M.; Shi, G. Y.; Wu, G. C.; Lee, H.; Jiang, M. J.; Wu, H. L.; Yang, H. Y. Nestin serves as a prosurvival determinant that is linked to the cytoprotective effect of epidermal growth factor in rat vascular smooth muscle cells. J. Biochem., 2009, 146 (3), 307-315.
80. Daniel, C.; Albrecht, H.; Ludke, A.; Hugo, C. Nestin expression in repopulating mesangial cells promotes their proliferation. Lab Invest, 2008, 88 (4), 387-397. (Pubitemid 351432777)
81. Sahlgren, C. M.; Pallari, H. M.; He, T.; Chou, Y. H.; Goldman, R. D.; Eriksson, J. E. A nestin scaffold links Cdk5/p35 signaling to oxidant-induced cell death. EMBO J., 2006, 25 (20), 4808-4819. (Pubitemid 44607026)
82. Kawamoto, M.; Ishiwata, T.; Cho, K.; Uchida, E.; Korc, M.; Naito, Z.; Tajiri, T. Nestin expression correlates with nerve and retroperitoneal tissue invasion in pancreatic cancer. Hum. Pathol., 2009, 40 (2), 189-198.
83. Yamahatsu, K.; Matsuda, Y.; Ishiwata, T.; Uchida, E.; Naito, Z. Nestin as a novel therapeutic target for pancreatic cancer via tumor angiogenesis. Int. J. Oncol., 2012. 40 (5), 1345-1357.
84. Fryer, B. H.; Field, J. Rho, Rac, Pak and angiogenesis: Old roles and newly identified responsibilities in endothelial cells. Cancer Lett., 2005, 229 (1), 13-23. (Pubitemid 41263406)
85. Vader, P.; van der Meel, R.; Symons, M. H.; Fens, M. H.; Pieters, E.; Wilschut, K. J.; Storm, G.; Jarzabek, M.; Gallagher, W. M.; Schiffelers, R. M.; Byrne, A. T. Examining the role of Rac1 in tumor angiogenesis and growth: A clinically relevant RNAi-mediated approach. Angiogenesis., 2011, 14 (4), 457-466.
86. Aznar, S.; Fernandez-Valeron, P.; Espina, C.; Lacal, J. C. Rho GTPases: Potential candidates for anticancer therapy. Cancer Lett., 2004, 206 (2), 181-191. (Pubitemid 38317288)
87. Duxbury, M. S.; Ito, H.; Zinner, M. J.; Ashley, S. W.; Whang, E. E. EphA2: A determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene, 2004, 23 (7), 1448-1456. (Pubitemid 38406840)
88. Gilabert-Estelles, J.; Braza-Boils, A.; Ramon, L. A.; Zorio, E.; Medina, P.; Espana, F.; Estelles, A. Role of microRNAs in gynecological pathology. Curr. Med. Chem., 2012, 19 (15), 2406-2413.
89. Kim, D. H.; Rossi, J. J. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet., 2007, 8 (3), 173-184.
90. Wolters, N. M.; MacKeigan, J. P. From sequence to function: Using RNAi to elucidate mechanisms of human disease. Cell Death. Differ., 2008, 15 (5), 809-819. (Pubitemid 351524423)
91. Kleinman, M. E.; Yamada, K.; Takeda, A.; Chandrasekaran, V.; Nozaki, M.; Baffi, J. Z.; Albuquerque, R. J.; Yamasaki, S.; Itaya, M.; Pan, Y.; Appukuttan, B.; Gibbs, D.; Yang, Z.; Kariko, K.; Ambati, B. K.; Wilgus, T. A.; DiPietro, L. A.; Sakurai, E.; Zhang, K.; Smith, J. R.; Taylor, E. W.; Ambati, J. Sequence-and targetindependent angiogenesis suppression by siRNA via TLR3. Nature, 2008, 452 (7187), 591-597. (Pubitemid 351483358)
92. Hickerson, R. P.; Flores, M. A.; Leake, D.; Lara, M. F.; Contag, C. H.; Leachman, S. A.; Kaspar, R. L. Use of self-delivery siRNAs to inhibit gene expression in an organotypic pachyonychia congenita model. J. Invest Dermatol., 2011, 131 (5), 1037-1044.
93. Hickerson, R. P.; Leachman, S. A.; Pho, L. N.; Gonzalez-Gonzalez, E.; Smith, F. J.; McLean, W. H.; Contag, C. H.; Leake, D.; Milstone, L. M.; Kaspar, R. L. Development of quantitative molecular clinical end points for siRNA clinical trials. J. Invest Dermatol., 2011, 131 (5), 1029-1036.
94. Leachman, S. A.; Hickerson, R. P.; Schwartz, M. E.; Bullough, E. E.; Hutcherson, S. L.; Boucher, K. M.; Hansen, C. D.; Eliason, M. J.; Srivatsa, G. S.; Kornbrust, D. J.; Smith, F. J.; McLean, W. I.; Milstone, L. M.; Kaspar, R. L. First-in-human mutation-targeted siRNA Phase Ib trial of an inherited skin disorder. Mol. Ther., 2010, 18 (2), 442-446.
95. Nkoghe, D.; Formenty, P.; Nnegue, S.; Mve, M. T.; Hypolite, I.; Leonard, P.; Leroy, E. [Practical guidelines for the management of Ebola infected patients in the field]. Med. Trop. (Mars. ), 2004, 64 (2), 199-204.
96. Geisbert, T. W.; Lee, A. C.; Robbins, M.; Geisbert, J. B.; Honko, A. N.; Sood, V.; Johnson, J. C.; de, J. S.; Tavakoli, I.; Judge, A.; Hensley, L. E.; Maclachlan, I. Postexposure protection of nonhuman primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study. Lancet, 2010, 375 (9729), 1896-1905.
97. Raven, K. Stop-work order creates uncertainty for Ebola drug research. Nat. Med., 2012, 18 (9), 1312.
98. Sisco, M.; Kryger, Z. B.; O'Shaughnessy, K. D.; Kim, P. S.; Schultz, G. S.; Ding, X. Z.; Roy, N. K.; Dean, N. M.; Mustoe, T. A. Antisense inhibition of connective tissue growth factor (CTGF/CCN2) mRNA limits hypertrophic scarring without affecting wound healing in vivo. Wound. Repair Regen., 2008, 16 (5), 661-673.
99. RXi Pharmaceuticals Corporation. http://www.rxipharma.com/rxi-109/ (Accessed January 5, 2013)
100. Medical News http://www.news-medical.net/news/20120924/RXicompletes- dosing-in-RXI-109-Phase-1-study-for-dermalscarring. aspx (Accessed January 05, 2013)
101. Li, M.; Xu, J.; Chen, X.; Sun, X. RNA interference as a gene silencing therapy for mutant MYOC protein in primary open angle glaucoma. Diagn. Pathol., 2009, 4, 46.
102. Sylentis Company http://www.sylentis.com/index.php/en/news/51-zeltia- informa-que-su-filial-sylentis-ha-recibido-autorizacionpara. html (Accessed January 5, 2013).
103. Stein, E. A.; Mellis, S.; Yancopoulos, G. D.; Stahl, N.; Logan, D.; Smith, W. B.; Lisbon, E.; Gutierrez, M.; Webb, C.; Wu, R.; Du, Y.; Kranz, T.; Gasparino, E.; Swergold, G. D. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med., 2012, 366 (12), 1108-1118.
104. Alnylam Clinical and Development Programs http://www.alnylam.com/ Programs-and-Pipeline/index.php (Accessed January 5, 2013).
105. Billings, J. L.; Hertz, M. I.; Wendt, C. H. Community respiratory virus infections following lung transplantation. Transpl. Infect. Dis., 2001, 3 (3), 138-148. (Pubitemid 32756696)
106. Ventre, K.; Randolph, A. G. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane. Database. Syst. Rev., 2007, (1), CD000181.
107. Sullender, W. M. Respiratory syncytial virus genetic and antigenic diversity. Clin. Microbiol. Rev., 2000, 13 (1), 1-15, table. (Pubitemid 30039340)
108. Alvarez, R.; Elbashir, S.; Borland, T.; Toudjarska, I.; Hadwiger, P.; John, M.; Roehl, I.; Morskaya, S. S.; Martinello, R.; Kahn, J.; Van, R. M.; Tripp, R. A.; DeVincenzo, J. P.; Pandey, R.; Maier, M.; Nechev, L.; Manoharan, M.; Kotelianski, V.; Meyers, R. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob. Agents Chemother., 2009, 53 (9), 3952-3962.
109. DeVincenzo, J.; Cehelsky, J. E.; Alvarez, R.; Elbashir, S.; Harborth, J.; Toudjarska, I.; Nechev, L.; Murugaiah, V.; Van, V. A.; Vaishnaw, A. K.; Meyers, R. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res., 2008, 77 (3), 225-231.
110. Zamora, M. R.; Budev, M.; Rolfe, M.; Gottlieb, J.; Humar, A.; Devincenzo, J.; Vaishnaw, A.; Cehelsky, J.; Albert, G.; Nochur, S.; Gollob, J. A.; Glanville, A. R. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am. J. Respir. Crit Care Med., 2011, 183 (4), 531-538.
111. Burnett, J. C.; Rossi, J. J.; Tiemann, K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J., 2011, 6 (9), 1130-1146.
112. DeVincenzo, J.; Lambkin-Williams, R.; Wilkinson, T.; Cehelsky, J.; Nochur, S.; Walsh, E.; Meyers, R.; Gollob, J.; Vaishnaw, A. A randomized, double-blind, placebo-controlled study of an RNAibased therapy directed against respiratory syncytial virus. Proc. Natl. Acad. Sci. U. S. A, 2010, 107 (19), 8800-8805.
113. Ni, Z.; Hui, P. Emerging pharmacologic therapies for wet agerelated macular degeneration. Ophthalmologica, 2009, 223 (6), 401-410.
114. Tolentino, M. J.; Brucker, A. J.; Fosnot, J.; Ying, G. S.; Wu, I. H.; Malik, G.; Wan, S.; Reich, S. J. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina, 2004, 24 (1), 132-138.[105a] (Pubitemid 38240851)
115. Sathornsumetee, S.; Rich, J. N. New treatment strategies for malignant gliomas. Expert. Rev. Anticancer Ther., 2006, 6 (7), 1087-1104. (Pubitemid 44203386)
116. Miller, C. R.; Perry, A. Glioblastoma. Arch. Pathol. Lab Med., 2007, 131 (3), 397-406.
117. Zukiel, R.; Nowak, S.; Wyszko, E.; Rolle, K.; Gawronska, I.; Barciszewska, M. Z.; Barciszewski, J. Suppression of human brain tumor with interference RNA specific for tenascin-C. Cancer Biol. Ther., 2006, 5 (8), 1002-1007.
118. Rolle, K.; Nowak, S.; Wyszko, E.; Nowak, M.; Zukiel, R.; Piestrzeniewicz, R.; Gawronska, I.; Barciszewska, M. Z.; Barciszewski, J. Promising human brain tumors therapy with interference RNA intervention (iRNAi). Cancer Biol. Ther., 2010, 9 (5), 396-406.
119. Engstrom, Y.; Eriksson, S.; Jildevik, I.; Skog, S.; Thelander, L.; Tribukait, B. Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. J. Biol. Chem., 1985, 260 (16), 9114-9116. (Pubitemid 15249885)
120. Heidel, J. D.; Liu, J. Y.; Yen, Y.; Zhou, B.; Heale, B. S.; Rossi, J. J.; Bartlett, D. W.; Davis, M. E. Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin. Cancer Res., 2007, 13 (7), 2207-2215. (Pubitemid 46649891)
121. Duxbury, M. S.; Ito, H.; Zinner, M. J.; Ashley, S. W.; Whang, E. E. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene, 2004, 23 (8), 1539-1548. (Pubitemid 38406516)
122. Davis, M. E.; Pun, S. H.; Bellocq, N. C.; Reineke, T. M.; Popielarski, S. R.; Mishra, S.; Heidel, J. D. Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers. Curr. Med. Chem., 2004, 11 (2), 179-197. (Pubitemid 38128844)
123. Heidel, J. D. Linear cyclodextrin-containing polymers and their use as delivery agents. Expert. Opin. Drug Deliv., 2006, 3 (5), 641-646. (Pubitemid 44383491)
124. Clinical trials. A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/home (Accessed January 5, 2013).
125. Aleku, M.; Schulz, P.; Keil, O.; Santel, A.; Schaeper, U.; Dieckhoff, B.; Janke, O.; Endruschat, J.; Durieux, B.; Roder, N.; Loffler, K.; Lange, C.; Fechtner, M.; Mopert, K.; Fisch, G.; Dames, S.; Arnold, W.; Jochims, K.; Giese, K.; Wiedenmann, B.; Scholz, A.; Kaufmann, J. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res., 2008, 68 (23), 9788-9798.
126. Santel, A.; Aleku, M.; Roder, N.; Mopert, K.; Durieux, B.; Janke, O.; Keil, O.; Endruschat, J.; Dames, S.; Lange, C.; Eisermann, M.; Loffler, K.; Fechtner, M.; Fisch, G.; Vank, C.; Schaeper, U.; Giese, K.; Kaufmann, J. Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin. Cancer Res., 2010, 16 (22), 5469-5480.
127. Leenders, F.; Mopert, K.; Schmiedeknecht, A.; Santel, A.; Czauderna, F.; Aleku, M.; Penschuck, S.; Dames, S.; Sternberger, M.; Rohl, T.; Wellmann, A.; Arnold, W.; Giese, K.; Kaufmann, J.; Klippel, A. PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase. EMBO J., 2004, 23 (16), 3303-3313. [110a] (Pubitemid 39209154)
128. Strumberg, D.; Schultheis, B.; Traugott, U.; Vank, C.; Santel, A.; Keil, O.; Giese, K.; Kaufmann, J.; Drevs, J. Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int. J. Clin. Pharmacol. Ther., 2012, 50 (1), 76-78.
129. Blangy, A.; Lane, H. A.; d'Herin, P.; Harper, M.; Kress, M.; Nigg, E. A. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell, 1995, 83 (7), 1159-1169.
130. Kinch, M. S.; Moore, M. B.; Harpole, D. H., Jr. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin. Cancer Res., 2003, 9 (2), 613-618. (Pubitemid 36182592)
131. Noblitt, L. W.; Bangari, D. S.; Shukla, S.; Knapp, D. W.; Mohammed, S.; Kinch, M. S.; Mittal, S. K. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treat ment with adenoviral vectors that express EphrinA1. Cancer Gene Ther., 2004, 11 (11), 757-766. (Pubitemid 39488474)
132. Abraham, S.; Knapp, D. W.; Cheng, L.; Snyder, P. W.; Mittal, S. K.; Bangari, D. S.; Kinch, M.; Wu, L.; Dhariwal, J.; Mohammed, S. I. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin. Cancer Res., 2006, 12 (2), 353-360. (Pubitemid 43166121)
133. Nakamura, R.; Kataoka, H.; Sato, N.; Kanamori, M.; Ihara, M.; Igarashi, H.; Ravshanov, S.; Wang, Y. J.; Li, Z. Y.; Shimamura, T.; Kobayashi, T.; Konno, H.; Shinmura, K.; Tanaka, M.; Sugimura, H. EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci., 2005, 96 (1), 42-47. (Pubitemid 40310024)
134. Landen, C. N.; Kinch, M. S.; Sood, A. K. EphA2 as a target for ovarian cancer therapy. Expert. Opin. Ther. Targets., 2005, 9 (6), 1179-1187. (Pubitemid 41762872)
135. Yang, X. Z.; Dou, S.; Sun, T. M.; Mao, C. Q.; Wang, H. X.; Wang, J. Systemic delivery of siRNA with cationic lipid assisted PEGPLA nanoparticles for cancer therapy. J. Control Release, 2011, 156 (2), 203-211.
136. Tekmira Pharmaceutical Corporations. http://www.tekmirapharm. com/Programs/Products.asp (Accessed January 5, 2013).
137. Kitada, S.; Andersen, J.; Akar, S.; Zapata, J. M.; Takayama, S.; Krajewski, S.; Wang, H. G.; Zhang, X.; Bullrich, F.; Croce, C. M.; Rai, K.; Hines, J.; Reed, J. C. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with In vitro and In vivo chemoresponses. Blood, 1998, 91 (9), 3379-3389. (Pubitemid 28193890)
138. Sengupta, A.; Banerjee, D.; Chandra, S.; Banerjee, S. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector. J. Gene Med., 2006, 8 (10), 1251-1261. (Pubitemid 44660524)
139. Chapman, C. M.; Sun, X.; Roschewski, M.; Aue, G.; Farooqui, M.; Stennett, L. S.; Gibellini, F.; Arthur, D.; Perez-Galan, P.; Wiestner, A. ON 01910.Na is selectively cytotoxic for Chronic Lymphocytic Leukemia cells through a dual mechanism involving PI3K/AKT inhibition and induction of oxidative stress. Clin. Cancer Res., 2012, 18 (7), 1979-1991.
140. Jakowlew, S. B.; Mathias, A.; Chung, P.; Moody, T. W. Expression of transforming growth factor beta ligand and receptor messenger RNAs in lung cancer cell lines. Cell Growth Differ., 1995, 6 (4), 465-476.
141. Phadke, A. P.; Jay, C. M.; Wang, Z.; Chen, S.; Liu, S.; Haddock, C.; Kumar, P.; Pappen, B. O.; Rao, D. D.; Templeton, N. S.; Daniels, E. Q.; Webb, C.; Monsma, D.; Scott, S.; Dylewski, D.; Frieboes, H. B.; Brunicardi, F. C.; Senzer, N.; Maples, P. B.; Nemunaitis, J.; Tong, A. W. In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein. DNA Cell Biol., 2011, 30 (9), 715-726.